TY - JOUR
T1 - Medullary thyroid cancer in the era of tyrosine kinase inhibitors
T2 - To treat or not to treat - and with which drug - those are the questions
AU - Cabanillas, Maria E.
AU - Hu, Mimi I.
AU - Jimenez, Camilo
N1 - Publisher Copyright:
Copyright © 2014 by the Endocrine Society.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Context: Medullary thyroid cancer (MTC) is a rare form of thyroid cancer comprising approximately 4% of all thyroid cancers. The majority of patients have a relatively good prognosis; however, a subgroup of patients will require systemic therapy. Large phase III randomized trials led to the approval of two drugs - vandetanib and cabozantinib - for progressive or symptomatic MTC. The decision regarding which drug to initiate first is not entirely clearandis acommonconcernamongst treating physicians. Evidence Acquisition and Synthesis: A review of the literature in English was conducted, and data were summarized and integrated into a decision matrix. Conclusions: The decision regarding which drug to initiate first for progressive MTC should be based on a careful review of the medical history, physical examination findings, medication list, electrocardiogram, laboratory results, and tumor characteristics. It is necessary to consider the relative contraindications when choosing which drug to initiate first.
AB - Context: Medullary thyroid cancer (MTC) is a rare form of thyroid cancer comprising approximately 4% of all thyroid cancers. The majority of patients have a relatively good prognosis; however, a subgroup of patients will require systemic therapy. Large phase III randomized trials led to the approval of two drugs - vandetanib and cabozantinib - for progressive or symptomatic MTC. The decision regarding which drug to initiate first is not entirely clearandis acommonconcernamongst treating physicians. Evidence Acquisition and Synthesis: A review of the literature in English was conducted, and data were summarized and integrated into a decision matrix. Conclusions: The decision regarding which drug to initiate first for progressive MTC should be based on a careful review of the medical history, physical examination findings, medication list, electrocardiogram, laboratory results, and tumor characteristics. It is necessary to consider the relative contraindications when choosing which drug to initiate first.
UR - http://www.scopus.com/inward/record.url?scp=84916600672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84916600672&partnerID=8YFLogxK
U2 - 10.1210/jc.2014-2811
DO - 10.1210/jc.2014-2811
M3 - Article
C2 - 25238206
AN - SCOPUS:84916600672
SN - 0021-972X
VL - 99
SP - 4390
EP - 4396
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 12
ER -